OMCL up +3.82% percent Today $OMCL High is at 33.15 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
OMCL up +3.82% percent Today $OMCL High is at 33.15 and the Low 32.51 with current volume of 90,627.

Recent News posted below.

Omnicell Inc OMCL other info.
http://investorshangout.com/Omnicell-Inc-OMCL-54976/

OMCL Omnicell Inc Recent Headline News

Omnicell Reports Mixed Q3, Positive on Surgichem Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 2:00PM CST
On Nov 6, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.39 (-0.02), ICUI: 83.64 (-1.09), ABAX: 55.08 (+0.88), OMCL: 32.71 (+0.80)

Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Omnicell Is Up 5.9% (OMCL)
Comtex SmarTrend(R) - Mon Nov 10, 12:13PM CST
11 days ago, on October 30th, 2014, Omnicell (NASDAQ:OMCL) reported its earnings. Analysts, on average, expected earnings of $0.31 per share on sales of $105.9 million. The company actually reported EPS of $0.30 on sales of $112.5 million, missing EPS estimates by $0.01 and beating revenue estimates by $6.7 million. Since the company's report, shares of Omnicell have risen from $30.11 to $31.89, representing a gain of 5.9% in the past 11 days.
OMCL: 32.71 (+0.80)

Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.39 (-0.02), ICUI: 83.64 (-1.09), ABAX: 55.08 (+0.88), OMCL: 32.71 (+0.80)

Update: Omnicell Q3 Earnings Send Shares Soaring
Marshall Hargrave - at Seeking Alpha - Wed Nov 05, 9:57AM CST

OMCL: 32.71 (+0.80)

Omnicell To Present At The 2014 Stephens Inc. Fall Investment Conference
PR Newswire - Wed Nov 05, 7:17AM CST
Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, today announced it will present at the 2014 Stephens Inc. Fall Investment Conference at the New York Palace Hotel, New York, NY.
OMCL: 32.71 (+0.80)

Omnicell Launches Its First Fully Automated Multimed Packing Solution, Driving Workflow Efficiency, Patient Adherence, and Pharmacy Growth
PR Newswire - Wed Nov 05, 7:00AM CST
Omnicell, Inc., (NASDAQ:OMCL), today announced the company's first fully automated multimed packing solution to assist pharmacists in improving their patients' medication adherence. The Omnicell M5000 system is designed to automatically pack, seal, verify and label multimed blister cards for institutional pharmacies serving long term care facilities, retail pharmacies and hospital pharmacies serving ambulatory and discharged patients.
OMCL: 32.71 (+0.80)

Saratoga Hospital Selects Omnicell Unity Enterprise Platform to Upgrade Existing Medication Automation Solutions
PR Newswire - Tue Nov 04, 7:00AM CST
Omnicell, Inc., (NASDAQ: OMCL), today announced that Saratoga Hospital, located in Saratoga Springs, New York, has selected Omnicell to be its new provider of automated medication management solutions and data analytics tools in the main hospital facility as well as an urgent care center, surgery center, infusion center and cancer treatment center. For the first time, from a single central pharmacy location, several different medication dispensing systems can be managed at Saratoga Hospital, providing greater efficiency to clinical and administrative staff.
OMCL: 32.71 (+0.80)

Omnicell Gains Despite Earnings Miss; View Up on High Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:20AM CST
Omnicell's (OMCL) share prices have climbed 7.3% since the earnings release to close at $32.31 on Friday
AMSG: 50.19 (-0.23), USPH: 39.65 (-0.05), RDNT: 8.28 (-0.07), OMCL: 32.71 (+0.80)

Omnicell misses 3Q profit forecasts
Automated Insights - Thu Oct 30, 6:37PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Omnicell Inc. (OMCL) on Thursday reported profit of $7.3 million in its third quarter.
OMCL: 32.71 (+0.80)

Omnicell's (OMCL) CEO Randall Lipps on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 6:30PM CDT

OMCL: 32.71 (+0.80)

Omnicell misses by $0.01
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT

OMCL: 32.71 (+0.80)

Omnicell Announces Third Quarter 2014 Results
PR Newswire - Thu Oct 30, 3:01PM CDT
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced results for its third quarter ended September 30, 2014.
OMCL: 32.71 (+0.80)

Global Pharmacy Automation Systems Market Forecasts and Opportunities, 2019 - Analysis of the $4.1 Billion Industry
M2 - Tue Oct 28, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zh84wk/pharmacy) has announced the addition of the "Pharmacy Automation Systems Market by product type & by End-user - Global Forecasts & Trends to 2019" report to their offering. The pharmacy automation market is expected to reach $4.5 billion by 2019 from $3.1 billion in 2014 The global pharmacy automation systems market has witnessed considerable growth over the past few years and is further expected to grow In this report the market is segmented by product, end user, and by geography. On the basis of product, the market includes automated medication dispensing systems, automated packaging and labeling systems, automated medication compounding systems, storage and retrieval systems, table-top counters, and other systems. Whereas, on the basis of end users, the market includes the inpatient pharmacy units, outpatient pharmacy units, retail pharmacies, and pharmacy benefit management organizations and other mail-order setting. The inpatient pharmacy automation market is further classified as acute care setting and long-term care setting, while the outpatient pharmacy automation market is segmented into fast-track clinics and hospital pharmacies. Factors such as the necessity of cost containment, reduction of medication errors, and the need to increase the efficiency of work within the pharmacies are the major drivers for the pharmacy automation systems market. However, stringent regulatory guidelines which delay product launches, high costs of implementation of automation systems, and restricted budgets of healthcare that lower investments in the automated systems by small companies are some of the key factors restraining the growth of the global market. However, the increasing awareness regarding the benefits of the pharmacy automation systems in the developing countries offer new growth opportunities to the market players. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Pharmacy Automation Systems Market, By Product 5 Global Pharmacy Automation Systems Market, By End-Users 6 Global Pharmacy Automation Systems Market, By Geography 7 Competitive Landscape 8 Company Profiles - Baxter International Inc. - Carefusion Corporation - Cerner Corporation - Kirby Lester - Mckesson Corporation - Omnicell, Inc. - Parata Systems Llc - Scriptpro Llc - Swisslog Holding Ag - Talyst, Inc. For more information visit http://www.researchandmarkets.com/research/zh84wk/pharmacy
BAX: 72.09 (+0.76), OMCL: 32.71 (+0.80), CERN: 64.38 (+0.57)

Wake Forest Baptist Medical Center Will Convert to Omnicell Medication Automation Solutions
PR Newswire - Mon Oct 27, 7:00AM CDT
Omnicell, Inc., (NASDAQ:OMCL), today announced that Wake Forest Baptist Medical Center, located in Winston-Salem, North Carolina, has selected the Company's pharmacy, nursing and data analytics solutions to drive workflow efficiencies that improve patient care. Omnicell's Unity enterprise platform will support the academic medical center with automated medication management solutions driven by pharmacists and used by nurses and other clinicians caring for patients across the health system's three hospitals. Installation will begin in 2015.
OMCL: 32.71 (+0.80)

Today's Strong And Under The Radar Stock Is Omnicell (OMCL)
at The Street - Fri Oct 24, 2:00PM CDT
Trade-Ideas LLC identified Omnicell (OMCL) as a strong and under the radar candidate
OMCL: 32.71 (+0.80)

Quality Systems Misses on Q2 Fiscal Earnings by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:30PM CDT
Quality Systems' (QSII) revenues at the end of the quarter stood at $120.5 million, representing an increase of 8.5% from the year-ago revenues.
PACB: 6.95 (+0.20), QSII: 15.02 (+0.04), ANGO: 16.91 (-0.07), OMCL: 32.71 (+0.80)

Omnicell to Release Third Quarter 2014 Earnings Results on October 30
PR Newswire - Thu Oct 23, 7:00AM CDT
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, will hold a conference call Thursday, October 30, to discuss the Company's Third Quarter 2014 financial results.
OMCL: 32.71 (+0.80)

athenahealth Q3 Earnings Fall but Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 9:30AM CDT
For the full year 2014, athenahealth (ATHN) reiterated its revenues guidance of $725 to $755 million
ZLTQ: 27.08 (-0.32), GWPH: 75.48 (+0.16), OMCL: 32.71 (+0.80), ATHN: 123.93 (+0.75)

Global Medication Management Market 2014-2019 - Systems, Services & Mode of Delivery Analysis of the $1.6 Billion Industry
M2 - Mon Oct 20, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vjmrp/medication) has announced the addition of the "Medication Management Market by Systems, Services, Mode of Delivery - Global Forecast to 2019" report to their offering. The global medication management market is valued at an estimated $845.1 million in 2014 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach $1,624.9 million by 2019 The adoption of medication management solutions by healthcare providers is increasing, owing to the rising concerns for minimizing adverse drug events and related medication errors. This is one of the key factors driving the growth of this market in the forecast period. Government initiatives to improve quality of care for patients and reduce healthcare expenditure are also expected to support the growth of the market in the coming years. The global market is broadly segmented by systems, services, mode of delivery, and end-users. The software market is divided into computerized physician order entry, clinical decision support systems, administration software, inventory management software, automated dispensing systems, and assurance systems software. The market, by services, is divided into medication analytics, point-of-care verification, and ADE (adverse drug events) surveillance. The end-users market is segmented into hospitals, pharmacies, and others. The market, by mode of delivery, is divided into on-premises, web-based, and cloud-based models. In 2013, the North American market dominated the global medication management market with a share of 63.7%, followed by Europe, APAC, and RoW. The APAC region shows the maximum growth potential in the coming few years. The urgent need for modernization of healthcare infrastructure, owing to the growth in aging population and increasing incidences of chronic diseases will help drive this market. Countries such as South Korea, China, and Singapore are expected to steer the growth of the medication management market in the APAC region. CareFusion Corporation (U.S.), McKesson Corporation (U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), Cerner Corporation (U.S.), and Siemens Healthcare (Germany) are some of the top players in the global medication management market. Report Scope By Software - Computerized Physician Order Entry - Clinical Decision Support System - Administration Software - Electronic Medication Administration Record (EMAR) - Barcode Medication Administration (BMA) - Inventory Management - Automated Dispensing Systems (ADS) - Centralized - Robots - Carousels - Decentralized Automated Dispensing Systems - Pharmacy-based ADS - Ward-based ADS - Automated Unit-Dose Dispensing - Assurance System Software By Services - Medication Analytics - Point-of-Care Verification - ADE Surveillance By End-users - Hospitals - Pharmacy - Others By Mode of Delivery - On-premises - Web-based - Cloud-based Companies Mentioned - Allscripts Healthcare Solutions, Inc. - Carefusion Corporation - Cerner Corporation - GE Healthcare (A Division Of General Electric Company) - Mckesson Corporation - Meditech - Omnicell, Inc. - Optum Inc. - Quadramed Corporation - Siemens Healthcare (Subsidiary Of Siemens Ag) For more information visit http://www.researchandmarkets.com/research/9vjmrp/medication
GE: 26.51 (-0.01), MCK: 204.27 (+1.14), MDRX: 12.33 (+0.38), OMCL: 32.71 (+0.80), CERN: 64.38 (+0.57)

Allscripts Healthcare Solutions EHR Attains Full KLAS Rating - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 12:40PM CDT
According to KLAS's August 2014 report, Allscripts Healthcare Solutions, Inc.'s (MDRX) Sunrise Ambulatory Care has been deemed to be the most highly-rated EHR across four categories.
ATEC: 1.44 (+0.02), MDRX: 12.33 (+0.38), OMCL: 32.71 (+0.80), CERN: 64.38 (+0.57)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 89

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 27

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Pathalys' Phase 3 Data Shows Promise for CKD Drug

Updated Category News Views 63

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 85

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 98

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 66

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 192

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 46

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
John Wong's Decade as Estate Planning Specialist

Updated Category News Views 68

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 146

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading

Top 5 Most Recently Viewed Articles

i3 Verticals' Strategic Shift Boosts Confidence in Future Growth

Updated Category News Views 53

i3 Verticals' Strategic Transformation Enhances Market Position i3 Verticals (NASDAQ: IIIV), recognized for providing integrated payment and software solutions, has recently received a boost in market confidence following the announcement of its significant $438 million divestiture. This strategic decision marks a pivotal moment for the company, allowing it to sharpen its...

Continue Reading
Understanding the Transformative Role of Placental Tissue for Healing

Updated Category News Views 93

Exploring the Benefits of Placental Allografts Marietta, GA – MiMedx Group, Inc. (NASDAQ: MDXG) has recently spotlighted the insights shared in a feature article about placental allografts, which focus on their application for healing complex wounds. This discussion surfaced through a compelling article in a major publication, highlighting the incredible advantages...

Continue Reading
Celebrate Impact: 13 Independent Coffee Shops Thriving Together

Updated Category News Views 326

Crimson Cup Supports Anniversaries of 13 Independent Coffee Shops Crimson Cup Coffee & Tea is proud to acknowledge the special anniversaries of 13 independent coffee houses this month. These remarkable shops are located in various states and have embraced their milestones, ranging from one year to an impressive 13 years of serving delicious coffee. The success these...

Continue Reading
Exploring Key UK Economic Trends Forecasted for 2025

Updated Category News Views 254

Insights on UK Economic Trends for 2025 The new year has arrived, and Deutsche Bank (ETR: DBKGn) has highlighted eight vital themes expected to influence the UK economy as we move further into 2025. Despite current uncertainties, analysts from Deutsche Bank express a level of optimism, indicating that government spending is likely to become a significant contributor to...

Continue Reading
Centene Corporation Reports Impressive Financial Results for 2024

Updated Category News Views 1146

Centene Corporation's Stellar 2024 Financial Overview Centene Corporation (NYSE: CNC) showcased robust financial performance for the year 2024, highlighted by a significant increase in diluted earnings per share (EPS) and revenue growth across various segments. The company's diluted EPS rose to $6.31, with an adjusted diluted EPS reaching $7.17, reflecting a 7% increase...

Continue Reading